Dr. Mosavi-Jarrahi received his Ph.D. in epidemiology from the University of Texas in 1996. Upon graduation, He began his post-doctoral research at the University of Texas Health Science Center. In 1998, he joined the Cancer Institute in Tehran, Iran, working as a research associate and at the same time he received a joint appointment as an assistant professor at the Medical School, Shahid Beheshti University of Medical Sciences Tehran, Iran. In 2011, he joined the Faculty of Health Sciences (FHS), Simon Fraser University as an adjunct professor of epidemiology. He has published more than 60 papers in peer-reviewed journals and received several grants from different funding agencies such as Terry Fox Foundation (international), World Health Organization. He is a founding member of the Iranian Epidemiological Association and served as its first general secretary for two terms. He is a member of several scientific journals’ editorial board. In July 2016, he was appointed as the Editor-in-Chief of the Asia Pacific Journal of Cancer Prevention.  In April 2018, Dr. Mosavi jarrah was appointed as the President of Asian Pacific Organization for Cancer Prevention (APOCP) for a duration of two years.

Professor David Roder joined The University of South Australia in 2011 as Professor of Cancer Epidemiology within the Sansom Institute for Health Research. His previous role was with the Cancer Council South Australia where he headed the research section. He has been a specialist epidemiology consultant to: the NSW Cancer Institute (since 2004); the former National Breast and Ovarian Cancer Centre (since 2005); and Cancer Australia (since 2007). As well as international consultancies with WHO in Mongolia, Malaysia and Indonesia, and consultant to the Malaysian and New Zealand Governments.
Professor Roder presently Chairs the National Cervical Cancer Safety Monitoring Committee, the Biostatistics Collaboration of Australia Advisory Committee, the Clinical Quality Registry Advisory Committee of the Australian Commission on Safety and Quality in Health Care, the Cross-jurisdictional Steering Committee of the WA Data Linkage System, and has been a member of the National Quality and Management Committee of BreastScreen Australia since 1995. 
He has authored approximately 200 peer-reviewed research publications and has been an invited presenter of scientific papers and/or chaired sessions at international scientific meetings in Australia, NZ, the UK, USA, Africa, NZ, Mongolia, Japan and a number of South East Asian countries. His influence in the area of health was recognised in 2000 with the Member of the Order of Australia award for contributions to cancer epidemiology, cancer registration and research.

He is a medical doctor specializing radition oncology with intrest in Preventive Oncology. He has obtained Fellowship from NCI/NIH in cancer control and molecular prevention in cancer. 

Dr Yip is currently a consultant breast surgeon in the Subang Jaya Medical Centre in Malaysia, and holds appointments as Clinical Professor in the Faculty of Medicine, University Tunku Abdul Rahman, Kuala Lumpur and Visiting Consultant to the Dept of Surgery, University of Malaya.  She is also the lead clinician for the breast cancer research programme in the Cancer Research Malaysia  (formerly known as Cancer Research Initiatives Foundation)  which is a charity based cancer research organization.  Dr Yip graduated from the University of Malaya with an MBBS degree in 1981, and started surgical training after her housemanship. After obtaining the FRCS (Glasgow) in 1985, she went on to pursue a career in academic surgery in the Dept of Surgery, Faculty of Medicine, University of Malaya, where sheretired in Sept 2012 as a professor. 

Keun-Young Yoo studied medicine at Seoul National University College of Medicine (1978). He received his MPH at SNU School of Public Health in 1981, and was awarded a PhD at SNU in 1985. Since 1986, he has been committed to cancer epidemiology research and has served as a faculty member in the Department of Preventive Medicine at SNU. He was a visiting researcher at the DEPH at Yale University in 1989-1990, and a visiting scientist at Aichi Cancer Center, Nagoya in 1990-1991 by the WHO. His major interest is in female cancer epidemiology, risk factor analysis, genetic susceptibility and preventive measures. In 1992, he conducted a multi-center collaborative study to establish a community-based the prospective cohort (KMCC), that is the first genomic cohort in Korea and one of the distinguished cohorts with biologic specimen bank in the world. He has continued to contribute to the newly constructed Korean genome cohort studies as the PI. He has served as the president of the Korean Genome Epidemiology Society since 2005. He led the Asian Cohort Consortium to establish a cohort of at least one million healthy people through partnership with other cohorts since 2005. As the Secretary General of the Asian Pacific Organization for Cancer Prevention since 2006, he is devoted to enhance cancer control strategies in developing countries through transfer knowledge, capacity building, and exchanging cancer control activities in the region. He was the President of the National Cancer Center of Korea from 2006-2008, and led the National Cancer Control Program in Korea.

Born in Hiroshima City in 1947, Dr. Tajima graduated from the Department of Orthopedics, School of Medicine, Osaka University in 1972. He then served as a doctor-in-training in the Surgery Department, Seirei Mikatahara General Hospital, Hamamatsu City, and later as a resident at the Pathological Department, Aichi Cancer Center Hospital. Following these, he became a researcher at the Division of Epidemiology and Prevention of the same cancer center. In 1986, he completed a master's course in the School of Public Health at Johns Hopkins University in the USA. After returning Japan, he served as Manager and Vice director at the Aichi Cancer Center. In 2006, he became Director of the Center, a position he continues to hold. Dr. Tajima is also Professor Emeritus at the Third Military Medical University and Huaxi School of Public Health, Sichuan University, China. More about prof. Tajoma..

Dr. Niveen Abu-Rmeileh is an Associate Professor of Statistical Epidemiology and the Director of the Institute of Community and Public Health at Birzeit University. Dr. Abu-Rmeileh holds a BSc in Medical Technology , a Master in Public Health and a PhD in Statistical Epidemiology from University of Glasgow. She teaches a variety of courses on quantitative research methods, health statistics and population studies. Her research interest is focused on the three broad categories: epidemiology of chronic diseases, reproductive health, and building psychometrics. More about Dr. Nivin Abu-Rmeileh click here..

Dr. Shahab Uddin is a Senior Scientist and Head of Molecular Pathophysiology, at Transnational Research Institute, Hamad Medical Corporation, Doha, Qatar. He graduated with BSc. Degree in Chemistry from the Aligarh Muslim University, India in 1982. He then received his MSc, MPhil and Ph.D. degrees in Biochemistry from Aligarh Muslim University, India in 1984, 1986 and 1988 respectively. After completing his graduate degree, he joined the Ohio State University, Columbus, USA for postdoctoral training for two years (1989-1991). He worked in the area molecular biology of DNA. He joined Loyola University of Chicago, Illinois, USA, and worked from April1991-1995 under Molecular Biology Training Program. He received extensive training in the molecular biology of brain hormone as well signaling mechanism of interferon in leukemia. In 1996, he joined the University of Illinois at Chicago initially as Instructor and then as Research Assistant Professor in the Department of Medicine. He continued working in the area of interferon signaling.  He joined the University of Chicago as Research Associate Professor and worked till 2003. In 2003, he joined King Faisal Specialist Hospital & Research Centre, Riyadh, KSA, as a Scientist initially (2003-2005) and subsequently promoted to Senior Scientist (2005) and deputy director of Human Cancer Genomic Program. Dr. Shahab contributed to the establishment of Human Cancer Genomic Program at King Faisal Specialist Hospital & Research Centre for translational research.   Currently, he is working as Senior Scientist and Head of Molecular Pathophysiology section in interim Translational Research Institute at Hamad Medical Corporation, Doha, Qatar. 

The primary research interest of Dr. Shahab is to identify dysregulated signaling molecular that are involved in survival and proliferation of malignant cells.  These molecular targets, once identified, will be helpful in the prognostic marker for detection of the onset of malignancy. On the other hand, these molecules will also serve as an attractive target for targeted therapy for the treatment and management of cancer cells.

Dr. Shahab Uddin published over 190 peer-reviewed articles in high impact factor journal such as Journal of Biological Chemistry, PNAS, Blood, Cancer Research, Journal of Immunology, and Clinical Cancer Research.  He has trained numerous postdoctoral fellows, Medical fellows, and graduate students. He has supervised numerous scientists, technicians, and students of different levels. He has served numerous scientific and administrative committees. He has been consciously reviewing manuscripts and grants proposals of international journal and agencies respectively.   

Professor Jeff Dunn AO is the Chief Executive Officer of Cancer Council Queensland. He currently holds Professorial appointments with the University of Southern Queensland Institute for Resilient Regions and the Griffith University School of Medicine and University of Queensland’s School of Social Science. He has a central focus on the social and behavioural aspects of cancer control, spanning across the continuum of research, prevention, early detection, supportive care and quality of life. He is actively involved in research in this field and has dedicated his career to the development of novel supportive care strategies that underpin cancer prevention and improve community awareness of the disease.  More about  prof. Dunn..

Prof. Adib is a frequent consultant for public agencies and international organizations on issues of public health, social development, environmental issues, human rights and research policies in Lebanon and the Middle-East. Since May 2012, Dr. Adib has been providing technical support to a newly established Division of Non-communicable Diseases at the WHO-EMRO in Cairo, Egypt.  Prof. Adib has served as manager of PH operations in various settings for national and international agencies in the USA and the Middle-East. More information about Prof. Adib …

Dr. Gultekin is a Gynae Oncologist, an associated Professor and lately a government official, who is actively involved in several leading cancer organizations, such as a council member of the European Society of Gynaecological Oncology (ESGO) and the International Agency for Research on Cancer (IARC) as well as a board member of the Middle East Cancer Consortium, Black Sea Countries Coalition on Breast and Cervical Carcinoma, Women Against Cervical Cancers (WACC), Asian Pacific Organization for Cancer Prevention and Asian National Cancer Centers Alliance (ANCCA). 
Furthermore, Dr. Gultekin has conducted several Pan-European oncology trials and is engaged in collaboration projects with the World Health Organization (WHO), International Agency for Research on Cancer(IARC), American Cancer Society (ACS) and American Society of Clinical Oncologist (ASCO).
As a member of the Turkish Society of Gynaecological Oncology, Dr. Gultekin officially represents the society on foreign affairs and urged the recognition of gynaecological oncology as a subspecialty in Turkey. 

Mehrnoosh Doroudchi received her Masters Degree as the top student among her peers in Medical Microbiology from Shiraz University of Medical Sciences (SUMS) in 1994. She was awarded her PhD in Immunology at SUMS in 1999 and She immediately started her work as an assistant professor in the Department of Immunology in School of Medicine, SUMS, where she committed her research to biomarkers in cancer research and inflammation. She joined the Laboratory of professor R.P. Sekaly in University of Montreal, Canada in a research fellowship program between 2005-2008 where she researched memory T cells. Since her return to the Department of Immunology as an associate professor, she has devoted her laboratory to research on T cells in inflammatory diseases and cancer as well as continuing study on biomarkers. As one of the trustee members of Shiraz Institute for Cancer Research, Mehrnoosh Doroudchi has made contributions in Cancer Biomarker research through multiple publications in high ranked journals in the field. She has supervised numerous Masters, Ph.D. and Medical specialty theses in the field of cancer in Iran to enhance education on the subject among graduates of medical school in Shiraz, Iran. She has also been serving as an associate editor in the Iranian Journal of Immunology since 2004.

Prof. Makvandi is the head of virology of deprtment in Ahwaz University of Medical Sciences, Ahwaz Iran. In addition he serve as the chief  of virology laboratory for diagnosis of measles, rubella and influenza viruses  in the south region of Iran, comission from the Iranian Ministry of Health and Medical Education since 1990 .

Professor Abdeladim Moumen is the head of R&D projects in the Moroccan Foundation for Advanced Science, Innovation and Research (MAScIR). He is leading R&D groups developing innovative molecular diagnostic medical kits using Molecular biology based techniques. He was behind the development and the validation of the first Moroccan molecular diagnostic kits aiming at the detection and quantification of the molecular markers of several cancer and viral diseases such as leukaemia, breast cancer, prostate cancers and hepatitis C and B infections. In addition to the molecular kits, Pr Moumen is also heading other biotechnology projects related to enzymes and vaccines production using molecular biology.

Before joining MAScIR, Pr Moumen was a research laboratory Director and an Associate Professor of Molecular and cellular Biology at the University of London. He has obtained his PhD at the Pasteur Institute in Paris in 2002. Pr Moumen has more than 13 years experience in performing, managing and directing research within several internationally recognised institutions (Pasteur Institute, Welcome trust-Gurdon institute, Cambridge University, and London University) and in diverse branches of medical biology such as Genetics, Cell Biology, Molecular Biology, Virology, Biochemistry and Biotechnology. His research competencies are highlighted by the high quality of scientific articles that he has published in highly recognised scienctific journals with high impact factors such as Cell, and Cancer Cell journals and the many research grants that he has obtained from several prestigious organism such as MRC, AICR and Wellcome trust. Furthermore, his experience in the above cited fields has been recognised worldwide as he has been invited to give seminars in many congress and within several key research institutions and to act as a reviewer for many scientific manuscripts as well as grant applications from prestigious journals (Cell, Nature, Molecular Cell..) and research funding organisms (Wellcome trust, MRC….) and as an editorial board member in many scientific journals. In 2009, the quality of his research has been recognised by the Moroccan government as he was awarded the Grand Prix for invention and research in science and technology. Recently he was awarded the first prize in the uncharted category of the African entrepreneurship award organised by the BMCE bank of Africa awarded to the best innovative project in Africa

Prof. Ravi Mehrotra is the Director at the Institute of Cytology and Preventive Oncology (Indian Council of Medical Research) of the Dept. of Health Research at Noida as well as the WHO-FCTC Global Hub on Smokeless Tobacco Products. He completed his medical training at the prestigious Armed Forces Medical College, Pune followed by MD and D.Phil at the University of Allahabad and Fellowship of the Royal College of Pathologists. He dihis postdoctoral training at various advanced centres around the world including Johns Hopkins Medical Center, Baltimore and University of Pennsylvania Medical Center. He is a past President of the Indian Academy of Cytologists. His research interests are focused on the early diagnosis and screening of cancer. He sits on the editorial board of 10 international peer-reviewed medical journals and has published a book of Oral Cytology (Springer,NY), many book chapters and more than 130 articles in his areas of expertise. He is the winner of many prestigious awards including the prestigious Dr.P.N.Wahi and Dr. Lachman award in cancer prevention and is also the past President of the Indian Academy of Cytologists. He is a strong believer in early diagnostic techniques in the field of cancer prevention as well as tobacco control. read more about Prof. ravi...

Professor Abdulbari Bener is Professor of Public Health at the Cerrahpaşa Faculty of Medicine, Istanbul University, and Istanbul Medipol University, International School of Medicine. He was Professor of Public Health in the Department of Public Health at the Weill Cornell Medical College for a period January 2006- August 2014. Professor Bener was Asst. Medical Director and Head of the Medical Statistics & Epidemiology Department at Hamad Medical Corporation, Qatar during August 2002- July 2014. Add to this, He is an advisor to World Health Organization and Adjunct Professor & Coordinator for the postgraduate and master public health programs (MPH) of the School of Epidemiology and Health Sciences, University of Manchester. He has held academic positions in public health, epidemiology, and statistics at universities in Turkey, Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, and England. He has been an author or coauthor of more than 550 published journal articles. He is acting as an Editor, Associate Editor, Advisor Editor and Asst. Editor for over 20 Journals and Referee for over 60 Journals. He has contributed to more than 19 book chapters and supervised theses of 50 postgraduate students (MSc, MPH, MPhil and PhD). 

Dr Abu-Helalah is currently the Middle East, North Africa & Central Asia, Regions Director for Global Academy for Health Sciences, Ohio, USA and Adjunct Associate Professor of Epidemiology and Preventive Medicine, College of Medicine AlFaisal University, KSA.

Dr Abu-Helalah completed his medical degree from Jordan University of Science and Technology (JUST) 2001. He moved in 2002 to the United Kingdom (UK) where completed a master degree in Public Health (MPH) from the University of Dundee in 2004 and a PhD in epidemiology and preventive medicine from the University of London in 2009. While he was in the UK, he worked as a Research Fellow in epidemiology and preventive Medicine at the St Bartholomew’s Hospital, London-UK, in 2007/2008.

In 2009, he joined King Hussein Cancer Center in Jordan as a Senior Officer for the cancer control program. In 2011, he joined the National Guard Health affairs as an Assistant Professor of Epidemiology and Preventive Medicine. In February 2012, he returned to work in Jordan at the Faculty of Medicine, Mutah University. In February 2016, he received an early promotion to be an Associate Professor of Epidemiology and Preventive Medicine. He was selected in 2013 as the regional director for the Global Center for Public Health and Disease Control. In 1 June 2016, he move to the Global Academy for Health Sciences, Ohio, USA as the Regional Director for the Middle East, North Africa and Central Asia regions Director. Since 1 September 2017, he joined AlFaisal University, KSA as an Adjunct Associate Professor in Epidemiology and Preventive Medicine. He also works as a consultant and technical expert for several regional and international organizations.
Dr Abu-Helalah has special expertise and interest in chronic diseases control and prevention particularly cancer, diabetes, thyroid disorders, cardiovascular diseases, medical research, and smoking cessation. he has had more than 30 publications in these fields in peer-reviewed journals and directed many scientific meetings in these fields.

On 9 April 2014, Dr Abu-Helalah was honoured by HRH Prince of Eastern Region, KSA, Prince Saud Bin Nayef, as the “Winner of the First place in the Prince of Easter Region Award for the Best Cancer Research in the Arab World” in the first round of this prize.

Dr. Omran S. Habib is Professor of epidemiology and health care at Department of Community Medicine, College of Medicine, University of Basrah, Basrah, Iraq. He has been teaching both undergraduate and postgraduate students and doing scientific research plus actively being involved in public health consultancy. He has served as a member of several national and international organizations such as Council of Community Medicine and Family Medicine (Iraq), Iraqi Cancer Board (2008-2015), Iraqi Medical association since 1977, Iraqi Union of teachers since 1977, the editorial board of the Asian Pacific Journal of Cancer prevention. He has punished numerous research papers and books throughout his career.

His area of research is focused tightly on role play of cell signaling pathways in different cancers and how different pathways can be therapeutically exploited. He has published 150+ articles in International Journals. He has published over 25 book chapters. He has considerable editorial experience, having edited 2 books for Springer in addition to serving as guest editor for ‘Seminars in Cancer Biology’, ‘Biomedical Research International’ and ‘Cellular and Molecular Biology’. He was recipient of research productivity award (RPA) by PCST in 2017 and 2018. He was ranked in top 10 scientists in under-40 category in Biological Sciences in 2018. He was ranked in Top 10 scientists in Overall category of RPA in Biological Sciences in 2018.  

DR. Kesarwani has been interested in tumor immunity, especially in cancer immunotherapy. One of his major project involved understanding how tumors utilize constant stimulation of antitumor T cells to induce cell death. They recently identified that T effector cell induces programmed necrosis of T cells. Inhabiting such unconventional form of cell death helps improve persistence of anti-tumor T cells and enhanced tumor control. They also found that antioxidants and cell surface thiols help increase T cell memory population. Moreover, they also found that mTOR inhibition has the results in increased cell surface thiols as well as antioxidant capacity, which gives them an edge over untreated effector T cells which have lower cell surface thiols and lower antioxidant capacity. He has also undertaken various other projects associated with understanding and increasing efficacy of immunotherapy.

Dr. Constance Saw is a Ph.D. in pharmaceutical sciences with post-doctoral training in drug delivery systems and chemoprevention. She has intensive research experience in the area of the pharmacodynamics of gene expression, signaling and metabolism of natural and synthetic cancer chemopreventive compounds/neutraceuticals in food and plant sources. After a few years of working as a pharmacist in National Cancer Centre Singapore (NCCS), Constance decided to make a conscious effort to shift her research and training focus to the bio-medical area and took up a Ph.D. course. Her wish was to work on basic research that could be translated into clinical practice to improve the treatment/quality of life of cancer patients.

Dr. Pratheeshkumar Poyil is an Associate Scientist at Human Cancer Genomics research, King Faisal Specialist Hospital and Research Centre (KFSH&RC) Riyadh, Saudi Arabia. Before joining at KFSH&RC, he was a Research Associate in the Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, USA for a period of 2011- 2016. He received his PhD degree in Tumor Immunology from Mahatma Gandhi University in 2011. He has been an author or co-author of more than 58 published research articles including reviews and book chapters; these articles have received 1448 citations with an H-index of 23 (Google Scholar, up to December 25, 2017). Add to this, he is an active reviewer of more than 20 international research journals. He is a member of editorial boards of International Journals and served as guest editor for 4 special journal issues in his research area. He is a highly motivated and innovative molecular biologist expertise in development and execution of translational biology, genetic and biochemistry-based research methods. His research interest includes the elucidation of cancer chemo-resistance mechanisms; identification of novel therapeutic targets in breast, papillary thyroid, colon and ovarian cancers and their targeting with small molecule inhibitors.

Prof. Ali Montazeri is an leading Iranian public health scientist at the Health Metrics Research Center of the Iranian Institute for Health Sciences Research. Montazeri received his PhD from University of Glasgow; his thesis concerned the quality of life in lung cancer patients. Montazeri published a major paper in 2004 that found that knowledge of cancer diagnosis does not change how a person fills out a questionnaire about his or her quality of life. he has contributted to many scietific papers in the field of quality of life metrics and social sciences. He also published papers in 2002, 2003, and 2015 about the epidemiology of breast cancer and breast cancer preventive behaviors such as breast self-examination.

Dr Bhat is currently working as a research scientist at Dept. of Translational Medicine, Sidra Medicine, Qatar. He completed his PhD from one of the premier institutes (All India Institute of Medical Sciences, AIIMS) in India. During Ph.D., he carried his reaserch on “Development of peptide based vaccine for Malraia, HIV and plague using immunoadjuvants and novel delivery vehicles”. After his Ph.D., he moved to Vanderbilt University Medical School, Nashville, TN, the USA for a postdoctoral fellowship.  During his eight years of postdoctoral training at Vanderbilt, he has gained broad experience in the field of cancer biology. His focus of the research was on the role and regulation of tight junction proteins (Claudins) in colorectal cancer and the role of bile acid-induced APE1/Ref1 in esophageal adenocarcinoma. He has published in well-reputed journals like Nature Communications, GUT, Oncogene, Cancer Research, Molecular Cancer and many more enlisted in his CV. He has attended many international meetings, conferences, symposia to present his research results. He has been awarded from Immunology society and American Association of Cancer research. He has also been awarded as an outstanding researcher for the year 2018 and 2019 from Sidra Medicine. He is an active member of many immunological and cancer societies. He is also serving in the editorial board and review committee of many journals.

Dr. Farzad Taghizadeh-Hesary is a board-certified of Radiation Oncology from Iran. He achieved his MD degree from Iran University of Medical Sciences (IUMS) in 2015 with an Exceptional-talent degree from the Ministry of Health. Subsequently, he passed the specialist course in Radiation Oncology at Shahid Beheshti University of Medical Sciences (SBMU) between 2015 and 2019 and achieved fourth place in the Radiation Oncology Board examination. He has authored approximately 20 peer-reviewed research publications and has reviewed approximately 100 manuscripts for ISI and Scopus indexed journals. Now, he is the Academic Editor of “Medicine ®“ and Associate editor of the “Asian Pacific Journal of Cancer Prevention”. Farzad and his group research on basic concepts of oncology. Their current project is the effect of mitochondria on cancer biogenesis and treatment.